Pseudomonas aeruginosa is one of the leading causes of nosocomial infections and has
become increasingly resistant to multiple antibiotics. However, development of novel …

Vaccines that could effectively prevent Pseudomonas aeruginosa pulmonary infections in
the settings of cystic fibrosis (CF) and nosocomial pneumonia could be exceedingly useful …

Pseudomonas aeruginosa is an antimicrobial-resistant bacterium that has no vaccine
approved for human use. Additionally, it has been identified by the World Health …

Pseudomonas aeruginosa was added to the World Health Organization's priority pathogen
list for research and development of new antibiotics in 2017. Alongside the development of …

Pseudomonas aeruginosa is an opportunistic pathogen that causes serious infections, is
usually resistant to antimicrobial agents, and is the leading cause of morbidity and …

Surface-expressed bacterial polysaccharides are often immunodominant, protective
antigens. However, these antigens are chemically and serologically highly heterogeneous …

Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic pathogen that commonly
causes fatal infections in cystic fibrosis and burn patients as well as in patients who are …

Pseudomonas aeruginosa is a common cause of hospital-acquired infections, including
central line-associated bloodstream infections and ventilator-associated pneumonia …

Pseudomonas aeruginosa is a major cause of respiratory tract infections worldwide,
particularly in hospitalized patients with immunosuppressed conditions and cystic fibrosis …

Pseudomonas aeruginosa is a leading cause of urinary tract, pulmonary, and wound
infections and is becoming increasingly resistant to antibiotics. Here, we report the iodonium …